{{Rsnum
|rsid=4648276
|Gene=PTGS2
|Chromosome=1
|position=186676356
|Orientation=minus
|GMAF=0.1024
|Gene_s=PTGS2
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(C;C)
|geno2=(C;T)
|geno3=(T;T)
}}{{ population diversity
| geno1=(C;C)
| geno2=(C;T)
| geno3=(T;T)
| CEU | 3.5 | 23.0 | 73.5
| HCB | 0.0 | 8.8 | 91.2
| JPT | 0.0 | 6.2 | 93.8
| YRI | 4.8 | 21.8 | 73.5
| ASW | 0.0 | 22.8 | 77.2
| CHB | 0.0 | 8.8 | 91.2
| CHD | 0.9 | 10.1 | 89.0
| GIH | 1.0 | 25.7 | 73.3
| LWK | 0.9 | 7.3 | 91.8
| MEX | 1.7 | 36.2 | 62.1
| MKK | 0.6 | 14.7 | 84.6
| TSI | 2.9 | 24.5 | 72.5
| HapMapRevision=28
}}{{PMID Auto
|PMID=22678777
|Title=PTGS1, PTGS2, ALOX5, ALOX12, ALOX15, and FLAP SNPs: interaction with fatty acids in colon cancer and rectal cancer
|OA=1
}}

{{PMID Auto
|PMID=17999989
|Title=Polymorphic variants in PTGS2 and prostate cancer risk: results from two large nested case-control studies.
}}

{{PMID Auto
|PMID=18085997
|Title=Pyrosequencing of polymorphisms in the COX-2 gene (PTGS2) with reported clinical relevance.
}}

{{PMID Auto
|PMID=19505919
|Title=Toll-like receptor signaling pathway variants and prostate cancer mortality.
|OA=1
}}

{{PMID Auto
|PMID=21168919
|Title=No influence of PTGS2 polymorphisms on response and remission to antidepressants in major depression.
}}

{{on chip | 23andMe v1}}
{{on chip | 23andMe v2}}
{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | Illumina Human 1M}}